Official facilitator of

the main

Found the key to immunotherapy for pancreatic cancer

August 7, 2018 15:35

Studies Center at the University of North Carolina cancer may help in the development of immunological methods for the treatment of pancreatic cancer - one of the most dangerous types of cancer.

For information on how to carry out the treatment of pancreatic cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

The journal «Cancer Immunology Research» scientists found that the molecule is interleukin-35 (IL35) is involved in the suppression of immune cells fighting against cancer cells of the pancreas. They also reported that the removal of the game IL-35 in combination with medication, pushes the immune system to fight cancer, help reduce swelling.

"Immunotherapy is effective in reducing tumor burden in these types of cancer, like melanoma, but this type of treatment is not enough to work well in the case of pancreatic cancer - researchers noted -. This is because the immune cells present in the tumors of the pancreas, cancer cells are suppressed. "

Pancreatic cancer is in most cases fatal. The five-year survival rate of only 8.5% is typical for patients. The disease is often diagnosed at later stages, which is associated with poor clinical outcomes. Many pancreatic tumor can not be operated because both at the time of diagnosis they have already spread to surrounding organs or encapsulate the vital blood vessels.

"We need some kind of agent that can shrink the tumor so that it can be removed during operation" - the researchers reported.

Immune therapies known as checkpoint inhibitors are effective in the treatment of certain cancers, including melanoma progressing. But in case they do not work with pancreatic cancer.

This is due to the fact that tumors contain immunosuppressive cells, which create a barrier to the T-lymphocytes "enter."

Researchers have figured out how to create this immunological barrier. They found that the cytokine IL35 suppresses the immune response. In laboratory models lacking IL35, decreased tumor growth and improved response to cancer killer cells. Scientists have also discovered synergy when using inhibitors of control points on these models.



The form Submitting the this by you agree to the privacy policy


No comments yet

new comment


definitely (will not be published)